Thus, 10 studies [11]–[15], [17], [21], [23], [26], [27] with 2196 patients were eligible for evaluating the relationship between XRCC3 Thr241Met polymorphism and survival of NSCLC receiving surgery, platinum-based chemotherapy and radiotherapy+chmotherapy. The gene discussed is XRCC3; the disease is non-small cell lung carcinoma.